One of Japan’s leading research institutions, the prestigious Riken Institute, will scale down the center at the heart of a stem-cell research scandal earlier this year.
Related Articles Read More >
Navigating the new regulatory terrain pharma companies face with IRA and 340B
FDA warns against compounded oral ketamine for psychiatric disorders
FDA resolves drug shortage for Novartis’ prostate cancer drug Pluvicto
